GO:0048020 CCR chemokine receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048020 (CCR chemokine receptor binding) is a molecular function defined as binding to a CCR chemokine receptor, encompassing ligands such as CC chemokines and pathogen-encoded chemokine-binding proteins.
• CCR chemokine receptors are seven-transmembrane G protein-coupled receptors that control leukocyte trafficking, inflammation, and immune surveillance.
• The interaction between chemokines and CCRs is a central node in HIV-1 entry, cancer progression, and cardiovascular repair.
• Atypical chemokine receptors such as CCRL2 and GPR1 bind chemokine-like ligands and shape tumor architecture and immune signaling.
• Poxvirus-encoded chemokine antagonists, such as the MC148 protein from molluscum contagiosum, selectively bind CCR8 and block its function, illustrating pathogen mimicry of GO:0048020.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of CCR chemokine receptor binding in disease.
Description
GO:0048020, CCR chemokine receptor binding, is a molecular function that describes the selective interaction of a ligand with a CC chemokine receptor (CCR). CCRs are a subfamily of seven-transmembrane G protein-coupled receptors that mediate leukocyte chemotaxis, immune cell activation, and tissue homeostasis. The binding event is the first committed step in a signaling cascade that translates extracellular chemokine gradients into directed cell migration and inflammatory responses. This function is not limited to endogenous chemokines; pathogen-encoded proteins and atypical receptors can also engage CCRs, expanding the biological scope of GO:0048020. For researchers, GO:0048020 provides a precise annotation for any gene product that physically binds a CCR chemokine receptor, whether it acts as an agonist, antagonist, or scavenger. The term is central to immunology, virology, oncology, and cardiovascular biology because CCR-ligand interactions determine how immune cells are recruited to sites of infection, injury, and tumor growth. Dysregulated CCR binding contributes to chronic inflammation, HIV-1 entry, and cancer progression, making it a high-value target for therapeutic intervention and experimental modeling. Understanding GO:0048020 at the molecular level requires integrating structural biology, signaling assays, and genetic perturbation. Recent work on atypical receptors such as GPR1 and CCRL2 has revealed non-canonical binding modes that broaden the definition of chemokine-receptor recognition. This article synthesizes authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of CCR chemokine receptor binding, its key genes, disease relevance, and the CRISPR-based methods used to study it.
CCR chemokine receptor binding At A Glance
| GO ID | GO:0048020 |
|---|---|
| GO term | CCR chemokine receptor binding |
| Ontology | molecular_function |
| Definition | Binding to a CCR chemokine receptor. |
| Synonyms | beta chemokine receptor binding; beta chemokine receptor ligand; CCR chemokine receptor ligand |
| Major function | Mediates selective recognition of CC chemokines and related ligands by CCR family receptors, initiating immune cell chemotaxis and signaling. |
| Representative ligands | CC chemokines such as MCP-1/CCL2, RANTES/CCL5, and pathogen-encoded antagonists such as MC148. |
| Representative receptors | CCR1-CCR10, including atypical receptors CCRL2 and GPR1. |
| Disease relevance | HIV-1 entry, cancer, cardiovascular injury, and inflammatory disorders. |
What Is GO:0048020?
According to the Gene Ontology, GO:0048020 (CCR chemokine receptor binding) is defined as binding to a CCR chemokine receptor. In practice, this means the gene product in question physically and selectively interacts with a member of the CC chemokine receptor family, which includes receptors such as CCR1 through CCR10 and atypical receptors like CCRL2. The term covers endogenous chemokines, pathogen-derived chemokine-binding proteins, and any other ligand that directly engages a CCR. It is a molecular function annotation, not a process annotation, so it describes the binding event itself rather than the downstream signaling or cellular outcome.
Why Is CCR chemokine receptor binding Important in Cell Biology?
CCR chemokine receptor binding is a fundamental molecular function in immunology because it determines which leukocytes migrate into tissues during infection, injury, and cancer. The specificity of this binding event controls the composition of the inflammatory infiltrate and the resolution of tissue damage. In cardiovascular disease, splenic marginal metallophilic macrophages depend on chemokine-receptor interactions for wound healing after myocardial infarction. In oncology, atypical receptors such as CCRL2 shape tumor spheroid structure and immune signaling in melanoma. In virology, the binding of HIV-1 gp120 to CCR5 is a prerequisite for viral entry, making this function a direct therapeutic target. Consequently, GO:0048020 is a high-priority annotation for drug discovery, vaccine design, and mechanistic disease research.
• Controls directed leukocyte migration and immune surveillance through chemokine gradients.
• Determines the specificity of inflammatory responses in infection and tissue repair.
• Is exploited by HIV-1 for cellular entry via CCR5 binding.
• Shapes tumor architecture and immune signaling in melanoma through atypical receptors like CCRL2.
• Is mimicked by poxvirus-encoded antagonists such as MC148, which selectively binds CCR8.
• Provides a druggable node for anti-inflammatory and anticancer therapies.
• Enables functional annotation of uncharacterized chemokine-like ligands through GO:0048020.
• Supports biomarker discovery in cardiovascular and inflammatory diseases.
• Facilitates comparative studies of canonical versus atypical chemokine receptor binding.
• Underpins CRISPR-based causal screens for immune cell trafficking genes.
Molecular Mechanism of CCR chemokine receptor binding
Ligand recognition and binding interface
In simple terms: The chemokine ligand docks onto the receptor like a key in a lock, using specific surface patches.
CCR chemokine receptor binding begins with the recognition of a chemokine ligand by the extracellular loops and N-terminal domain of the receptor. CC chemokines such as MCP-1/CCL2 and RANTES/CCL5 present a conserved fold that engages the receptor's binding pocket. Structural studies of atypical receptors like GPR1 bound to full-length chemerin have revealed a chemokine-like reverse binding mode, where the ligand inserts into the receptor in an orientation distinct from canonical chemokine-receptor complexes. This diversity in binding modes expands the mechanistic repertoire of GO:0048020 and explains how a single receptor family can recognize multiple ligands with different affinities.
Receptor activation and conformational change
In simple terms: Once the ligand binds, the receptor changes shape to transmit a signal inside the cell.
Ligand binding induces conformational changes in the CCR that propagate from the extracellular ligand-binding pocket to the intracellular G protein-coupling interface. This activation step is essential for downstream signaling and is a direct consequence of the binding event annotated by GO:0048020. For CCR5, the binding of HIV-1 gp120 in the presence of CD4 triggers a conformational transition that enables viral entry, demonstrating that the functional outcome of CCR binding depends on the specific ligand and co-receptor context. Atypical receptors such as CCRL2 can bind chemokine-like ligands without canonical G protein signaling, instead modulating immune signaling through alternative pathways.
Pathogen-encoded ligands and immune evasion
In simple terms: Some viruses make their own chemokine-like proteins to hijack or block CCR receptors.
Poxviruses encode chemokine-binding proteins that act as high-affinity antagonists of CCRs. The molluscum contagiosum virus protein MC148 is a highly selective CCR8 antagonist that blocks chemokine binding and prevents immune cell recruitment. This pathogen-encoded ligand is a natural example of GO:0048020 and demonstrates how the binding function can be subverted for immune evasion. Such pathogen-derived proteins are valuable tools for dissecting CCR binding specificity and for developing anti-inflammatory biologics.
Atypical receptors and non-canonical binding
In simple terms: Some receptors bind chemokines but do not signal like typical receptors; they act as decoys or regulators.
Atypical chemokine receptors such as CCRL2 and GPR1 bind chemokine-like ligands but lack canonical G protein signaling. CCRL2 shapes tumor spheroid structure and immune signaling in melanoma, indicating that its ligand-binding function modulates the tumor microenvironment. GPR1 binds full-length chemerin in a reverse binding mode, revealing that chemokine-like recognition can occur through distinct structural mechanisms. These examples show that GO:0048020 encompasses a broader range of binding events than classical chemokine-receptor interactions, with important implications for drug design and disease modeling.
Regulation of binding availability
In simple terms: Cells control when and where receptors are available to bind chemokines.
The availability of CCRs for ligand binding is regulated at multiple levels, including receptor internalization, recycling, and proteolytic processing. In the context of myocardial infarction, splenic CD169+Tim4+ marginal metallophilic macrophages are essential for wound healing, and their function depends on chemokine-receptor interactions that are temporally regulated after injury. The binding of HIV-1 gp120 to CCR5 is also regulated by CD4 engagement, which induces the conformational state required for high-affinity interaction. These regulatory layers ensure that GO:0048020 activity is spatially and temporally restricted to appropriate physiological contexts.
Key Genes Involved in GO:0048020 CCR chemokine receptor binding
The following genes encode ligands, receptors, and pathogen-derived proteins that participate in CCR chemokine receptor binding (GO:0048020), as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCL2 (MCP-1) | CC chemokine ligand that binds CCR2 and related receptors | Monocyte recruitment; imaging agent for inflammation |
| CCL5 (RANTES) | CC chemokine ligand that binds CCR1, CCR3, and CCR5 | T cell and macrophage chemotaxis; HIV-1 co-receptor biology |
| CCR5 | CC chemokine receptor that binds CCL5 and HIV-1 gp120 | HIV-1 entry; therapeutic target for maraviroc |
| CCR8 | CC chemokine receptor targeted by poxvirus antagonist MC148 | Immune evasion; allergy and cancer immunology |
| CCRL2 | Atypical chemokine receptor that binds chemokine-like ligands | Melanoma tumor spheroid structure and immune signaling |
| GPR1 | Atypical receptor that binds chemerin in a reverse binding mode | Structural basis of chemokine-like recognition |
| CXCL8 (IL-8) | Chemokine with evolving receptor-binding properties | Inflammation and neutrophil recruitment |
| CD169 (Siglec-1) | Macrophage marker involved in chemokine-dependent wound healing | Cardiac repair after myocardial infarction |
| Tim4 | Macrophage marker cooperating with CD169 in tissue repair | Splenic macrophage function in cardiovascular disease |
| MC148 | Poxvirus-encoded CCR8 antagonist | Pathogen mimicry of chemokine binding |
| CCR2 | Receptor for CCL2 and related chemokines | Monocyte trafficking; inflammation imaging |
| CCR1 | Receptor for CCL5 and other CC chemokines | Leukocyte recruitment; inflammatory disease |
| CCR3 | Receptor for eotaxin-family chemokines | Eosinophil trafficking; allergy |
| CCR4 | Receptor for CCL17 and CCL22 | Th2 immunity; cancer immunotherapy |
| CCR6 | Receptor for CCL20 | Mucosal immunity; autoimmune disease |
| CCR7 | Receptor for CCL19 and CCL21 | Lymph node homing; dendritic cell migration |
| CCR9 | Receptor for CCL25 | Gut-homing T cell responses |
| CCR10 | Receptor for CCL27 and CCL28 | Skin and mucosal immunity |
How Is CCR chemokine receptor binding Regulated?
The availability and activity of CCR chemokine receptor binding are regulated at multiple levels. Receptor internalization and recycling control the density of surface CCRs available for ligand engagement, thereby tuning the sensitivity of cells to chemokine gradients. In the context of myocardial infarction, the function of splenic CD169+Tim4+ marginal metallophilic macrophages in wound healing depends on temporally regulated chemokine-receptor interactions. The binding of HIV-1 gp120 to CCR5 is regulated by CD4 engagement, which induces a conformational state permissive for high-affinity interaction. Additionally, atypical receptors such as CCRL2 and GPR1 can modulate the availability of chemokine ligands by acting as scavengers or decoys, indirectly regulating canonical CCR binding. These regulatory mechanisms ensure that GO:0048020 activity is context-dependent and tightly controlled.
CCR chemokine receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCR5 | HIV-1 entry and AIDS pathogenesis | CCR5 knockout T cells or macrophages; point-mutation of gp120-binding residues |
| CCRL2 | Melanoma tumor spheroid structure and immune signaling | CCRL2 knockout melanoma spheroids; overexpression in immune cells |
| CD169/Tim4 | Cardiac wound healing after myocardial infarction | Conditional knockout mice; splenic macrophage depletion |
| CCL2/CCR2 | Monocyte recruitment in inflammation | CCL2 or CCR2 knockout mice; imaging with 99mTc-MCP-1 |
| MC148/CCR8 | Poxvirus immune evasion | Recombinant MC148 treatment; CCR8 knockout cells |
HIV-1 entry and AIDS pathogenesis
The binding of HIV-1 gp120 to the CCR chemokine receptor CCR5 is a critical step in viral entry into CD4+ T cells and macrophages. CD4-induced conformational changes in gp120 enable high-affinity interaction with CCR5, which triggers membrane fusion and viral infection. This direct link between GO:0048020 and HIV-1 pathogenesis has made CCR5 a major therapeutic target, and small-molecule antagonists such as maraviroc block this binding event.
Cardiovascular injury and wound healing
CCR chemokine receptor binding is essential for the recruitment of immune cells that mediate cardiac repair after myocardial infarction. Splenic CD169+Tim4+ marginal metallophilic macrophages are required for wound healing, and their mobilization depends on chemokine-receptor interactions. Disruption of these binding events impairs tissue repair and worsens cardiac outcomes, highlighting the clinical importance of GO:0048020 in cardiovascular disease.
Cancer and the tumor microenvironment
Atypical chemokine receptors such as CCRL2 shape tumor spheroid structure and immune signaling in melanoma, demonstrating that CCR chemokine receptor binding influences cancer progression and immune evasion. The binding of chemokines to CCRs on tumor-associated macrophages and regulatory T cells can promote an immunosuppressive microenvironment, making this function a potential target for cancer immunotherapy.
Inflammatory and infectious diseases
Dysregulated CCR chemokine receptor binding contributes to chronic inflammatory diseases, including atherosclerosis, arthritis, and inflammatory bowel disease. Pathogen-encoded antagonists such as MC148 from molluscum contagiosum block CCR8 binding to evade host immunity, illustrating how pathogens exploit this molecular function. Understanding these interactions informs the development of anti-inflammatory therapies and vaccines.
From CCR chemokine receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CCR5 prevent HIV-1 entry? | CCR5 knockout in CD4+ T cells or macrophages |
| Does CCRL2 binding modulate melanoma spheroid architecture? | CCRL2 knockout and overexpression in melanoma spheroid cultures |
| Is CD169+ macrophage chemokine binding required for cardiac repair? | Conditional CD169 knockout mice subjected to myocardial infarction |
| Can a point mutation in the CCR5 ligand-binding pocket abolish gp120 interaction? | CRISPR point-mutation knock-in of CCR5 variants |
| Does MC148 binding to CCR8 block chemokine signaling? | CCR8 knock-in reporter cells treated with recombinant MC148 |
| Can GPR1 reverse binding mode be recapitulated in vitro? | GPR1 knock-in cell lines with tagged chemerin |
How to Study the CCR chemokine receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct ligand-receptor binding affinity | Characterizing CCR5-gp120 interaction |
| Surface plasmon resonance | Real-time binding kinetics | Measuring chemokine-CCR affinity |
| Chemotaxis assay | Directed cell migration in response to chemokines | Functional validation of CCR binding |
| Calcium flux assay | G protein-coupled receptor activation | Testing agonist/antagonist activity at CCRs |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement of CCR5 for HIV-1 entry |
| CRISPR knock-in | Introduction of specific mutations | Modeling point mutations in CCR ligand-binding pocket |
| 3D spheroid culture | Tumor architecture and immune signaling | Studying CCRL2 in melanoma |
| In vivo imaging (99mTc-MCP-1) | Spatial distribution of CCR binding | Monitoring inflammation in animal models |
Binding assays and structural biology
Direct measurement of CCR chemokine receptor binding can be achieved using radiolabeled ligands, surface plasmon resonance, and isothermal titration calorimetry. The interaction of HIV-1 gp120 with CCR5 was characterized using CD4-induced binding assays. Structural studies of GPR1 bound to full-length chemerin revealed a reverse binding mode, providing atomic-level insight into GO:0048020. These methods are essential for defining the affinity and specificity of ligand-receptor pairs.
Functional chemotaxis and signaling assays
Chemotaxis assays, calcium flux measurements, and cAMP inhibition assays are used to determine whether CCR binding leads to functional activation. The role of CCRL2 in melanoma spheroid structure and immune signaling was assessed using functional assays in three-dimensional cultures. Splenic macrophage function in cardiac wound healing was evaluated using in vivo migration and injury models. These approaches link binding events to cellular outcomes.
Genetic perturbation with CRISPR
CRISPR-Cas9 knockout, point mutation, and knock-in strategies enable causal testing of specific genes in CCR chemokine receptor binding. For example, CCR5 knockout cells are resistant to HIV-1 entry, confirming the requirement for gp120-CCR5 binding. Conditional knockout of CD169 in mice demonstrated its essential role in cardiac wound healing. These genetic tools provide definitive evidence for gene function in GO:0048020.
Imaging and in vivo tracking
Non-invasive imaging with radiolabeled chemokines, such as 99mTc-MCP-1, allows visualization of CCR binding in living organisms. This approach has been used to monitor monocyte recruitment in inflammatory models. In vivo imaging combined with genetic models provides spatial and temporal information about CCR chemokine receptor binding in health and disease.
How CRISPR Can Be Used to Study GO:0048020 CCR chemokine receptor binding
Knockout
CRISPR knockout of CCR genes or their ligands is used to abolish binding and assess downstream consequences. For example, CCR5 knockout in CD4+ T cells confers resistance to HIV-1 entry, directly demonstrating the requirement for gp120-CCR5 binding. Conditional knockout of CD169 in mice impairs cardiac wound healing, linking chemokine-receptor interactions to tissue repair. Knockout models are essential for establishing causality in GO:0048020 research.
Point Mutation
CRISPR point mutation allows precise modification of residues in the ligand-binding pocket or receptor interface. This approach can be used to test whether specific amino acids in CCR5 are required for gp120 binding. Point mutations in chemokine ligands can also reveal determinants of receptor specificity. Such models are valuable for dissecting the molecular basis of GO:0048020.
Knock-in
CRISPR knock-in of tagged or reporter versions of CCRs or chemokines enables visualization and tracking of binding events in live cells. For example, knock-in of a fluorescent tag on CCRL2 would allow real-time imaging of its interaction with chemokine-like ligands in melanoma spheroids. Knock-in of human CCR5 into mouse models can humanize the HIV-1 entry pathway. These models bridge molecular binding to physiological function.
Overexpression
CRISPR-mediated overexpression of CCRs or their ligands can amplify binding signals and reveal gain-of-function phenotypes. Overexpression of CCRL2 in melanoma cells alters tumor spheroid structure and immune signaling, demonstrating that increased binding activity can remodel the tumor microenvironment. Overexpression of pathogen-encoded antagonists such as MC148 can block CCR8 signaling and immune evasion. Overexpression models are useful for screening and validation studies.
How EDITGENE Supports CCR chemokine receptor binding Research
Researchers studying CCR chemokine receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream immune responses. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for CCR chemokine receptor binding research.
Frequently Asked Questions About CCR chemokine receptor binding
What is GO:0048020?
GO:0048020 is the Gene Ontology molecular function term for CCR chemokine receptor binding, defined as binding to a CCR chemokine receptor.
What genes are involved in CCR chemokine receptor binding?
Key genes include CC chemokines such as CCL2 and CCL5, receptors such as CCR5 and CCR8, atypical receptors like CCRL2 and GPR1, and pathogen-encoded proteins such as MC148.
How does CCR5 binding lead to HIV-1 entry?
HIV-1 gp120 binds CCR5 in a CD4-induced manner, triggering conformational changes that enable viral membrane fusion and entry.
What is the role of atypical chemokine receptors in GO:0048020?
Atypical receptors such as CCRL2 and GPR1 bind chemokine-like ligands without canonical G protein signaling, modulating immune responses and tumor architecture.
Which diseases are associated with CCR chemokine receptor binding?
HIV-1/AIDS, cardiovascular injury, melanoma, and chronic inflammatory diseases are associated with this function.
How can CRISPR be used to study CCR chemokine receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of specific genes in binding and downstream signaling.
What is the MC148 protein and how does it relate to GO:0048020?
MC148 is a poxvirus-encoded CCR8 antagonist that binds CCR8 to evade host immunity, serving as a pathogen-derived example of CCR chemokine receptor binding.
What methods are used to measure CCR chemokine receptor binding?
Radioligand binding, surface plasmon resonance, chemotaxis assays, calcium flux, and in vivo imaging are commonly used.
Why is CCR chemokine receptor binding important for cancer research?
CCRL2 and other atypical receptors shape tumor spheroid structure and immune signaling, influencing cancer progression and immunotherapy response.
How does EDITGENE support CCR chemokine receptor binding research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to generate publication-ready cell models.
Conclusion
GO:0048020, CCR chemokine receptor binding, is a central molecular function that governs immune cell trafficking, pathogen evasion, and tissue repair. Its relevance spans HIV-1 entry, cardiovascular wound healing, melanoma biology, and inflammatory diseases, making it a high-value target for basic and translational research. The integration of structural biology, functional assays, and CRISPR-based genetic models has provided deep mechanistic insight into how chemokines and their mimics engage CCRs. Continued investigation of this function will inform the development of precision therapeutics for immune and infectious diseases. EDITGENE offers comprehensive CRISPR services to accelerate discovery in this field.
References
- 1. Matsushima K et al.. 2022. Interleukin-8: An evolving chemokine.. Cytokine 153:155828 PMID: 35247648
- 2. Ismahil MA et al.. 2025. Splenic CD169(+)Tim4(+) Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction.. Circulation 151(24):1712-1729 PMID: 40289811
- 3. Liu A et al.. 2024. Structure of G protein-coupled receptor GPR1 bound to full-length chemerin adipokine reveals a chemokine-like reverse binding mode.. PLoS Biol 22(10):e3002838 PMID: 39466725
- 4. Al Delbany D et al.. 2025. Atypical Chemokine Receptor CCRL2 Shapes Tumor Spheroid Structure and Immune Signaling in Melanoma.. Biomolecules 15(8) PMID: 40867595
- 5. Hartung D et al.. 2004. (99m)Tc-Monocyte chemoattractant protein-1.. PMID: 20641934
- 7. Wu L et al.. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.. Nature 384(6605):179-83 PMID: 8906795
- 8. Lüttichau HR et al.. 2000. A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum.. J Exp Med 191(1):171-80 PMID: 10620615
